AbbVie wins a 5-year free pass on mega-blockbuster Humira in biosim settlement with rival Amgen
It was clear from a recent sit-down with Leerink’s Geoffrey Porges that AbbVie was feeling good about keeping its mega-blockbuster Humira franchise in the US to itself through 2022. And this morning we got a peek into why they were so bullish.
Amgen, which scored the first approval for a biosimilar of Humira in the US, has signed off on a settlement agreement with AbbVie that will delay its rollout until early 2023. Amgen can get started in the EU in the fall of next year, with a marketing pact that calls on the company to pay royalties to AbbVie.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters